Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-676 (dazostinag) alone and with pembrolizumab in advanced solid tumors
jRCT2031230532Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label trial of dazostinag and pembrolizumab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) (9 arms), sponsored by Takeda. Primary endpoints: Number of participants reporting one or more treatment-emergent adverse events, Number of participants with dose-limiting toxicities and 2 more. Started Jul 2020; status: completed.
02
Drugs
dazostinagpembrolizumab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031230532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230532.